Khawaja Husnain Haider

Prof. Khawaja Husnain Haider

Sulaiman Alrajhi University, College of Medicine
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Beatrice AraminiBeatrice Aramini
Beatrice Aramini
VMvalentina masciale
valentina masciale
GGGiulia Grisendi
Giulia Grisendi
FBFederica Bertolini
Federica Bertolini
MMMichela Maur
Michela Maur
KHKhawaja Husnain Haider
Khawaja Husnain Haider
Emerging evidence suggests that a small subpopulation of cancer stem cells (CSCs) is responsible for initiation, progression, and metastasis cascade in tumors. CSCs share characteristics with normal stem cells, i.e., self-renewal and differentiation potential, suggesting that they can drive cancer progression. Consequently, targeting CSCs to prevent tumor growth or regrowth might offer a chance to lead the fight against cancer. CSCs create their niche, a specific area within tissue with a unique microenvironment that sustains their vital functions. Interactions between CSCs and their niches play a critical role in regulating CSCs’ self-renewal and tumorigenesis. Differences observed in the frequency of CSCs, due to the phenotypic plasticity of many cancer cells, remain a challenge in cancer therapeutics, since CSCs can modulate their transcriptional activities into a more stem-like state to protect themselves from destruction. This plasticity represents an essential step for future therapeutic approaches. Regarding self-renewal, CSCs are modulated by the same molecular pathways found in normal stem cells, such as Wnt/β-catenin signaling, Notch signaling, and Hedgehog signaling. Another key characteristic of CSCs is their resistance to standard chemotherapy and radiotherapy treatments, due to their capacity to rest in a quiescent state. This review will analyze the primary mechanisms involved in CSC tumorigenesis, with particular attention to the roles of CSCs in tumor progression in benign and malignant diseases; and will examine future perspectives on the identification of new markers to better control tumorigenesis, as well as dissecting the metastasis process.

9 January 2020 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
KHKhawaja Husnain Haider
Khawaja Husnain Haider
Beatrice AraminiBeatrice Aramini
Beatrice Aramini
Bone marrow-derived mesenchymal stem cells (MSCs) have successfully progressed to phase III clinical trials successive to an intensive in vitro and pre-clinical assessment in experimental animal models of ischemic myocardial injury. With scanty evidence regarding their cardiogenic differentiation in the recipient patients’ hearts post-engraftment, paracrine secretion of bioactive molecules is being accepted as the most probable underlying mechanism to interpret the beneficial effects of cell therapy. Secretion of small non-coding microRNA (miR) constitutes an integral part of the paracrine activity of stem cells, and there is emerging interest in miRs’ delivery to the heart as part of cell-free therapy to exploit their integral role in various cellular processes. MSCs also release membrane vesicles of diverse sizes loaded with a wide array of miRs as part of their paracrine secretions primarily for intercellular communication and to shuttle genetic material. Exosomes can also be loaded with miRs of interest for delivery to the organs of interest including the heart, and hence, exosome-based cell-free therapy is being assessed for cell-free therapy as an alternative to cell-based therapy. This review of literature provides an update on cell-free therapy with primary focus on exosomes derived from BM-derived MSCs for myocardial repair.

1 June 2018 in Regenerative Medicine
Verified
Journal Article
Closed access
KHKhawaja Husnain Haider
Khawaja Husnain Haider
Nearly two decades of experimental and clinical research with bone marrow cells have paved the way for Phase III pivotal trials in larger groups of heart patients. Despite immense advancements, a multitude of factors are hampering the acceptance of bone marrow cell-based therapy for routine clinical use. These include uncertainties regarding purification and characterization of the cell preparation, delivery protocols, mechanistic understanding and study end points and their methods of assessment. Clinical data show mediocre outcomes in terms of sustained cardiac pump function. This review reasons that the modest outcomes observed in trials thus far are based on quality of the cell preparation with a focus on the chronological aging of cells when autologous cells are used for transplantation in elderly patients.

3 March 2023 in Heart, Lung and Circulation
Verified
Journal Article
Closed access
YKYazan Kalou
Yazan Kalou
AAAbdullah Murhaf Al-Khani
Abdullah Murhaf Al-Khani
KHKhawaja Husnain Haider
Khawaja Husnain Haider

7 December 2017 in Regenerative Medicine
Verified
Journal Article
Closed access
KHKhawaja Husnain Haider
Khawaja Husnain Haider
SASalim Aziz
Salim Aziz
MAMateq Ali Al-Reshidi
Mateq Ali Al-Reshidi
Stem/progenitor cell-based therapy has been extensively studied for angiomyogenic repair of the ischemic heart by regeneration of the damaged myocytes and neovascularization of the ischemic tissue through biological bypassing. Given their inherent ability to assume functionally competent endothelial phenotype and release of broad array of proangiogenic cytokines, endothelial progenitor cells (EPCs)-based therapy is deemed as most appropriate for vaculogenesis in the ischemic heart. Emulating the natural repair process that encompasses mobilization and homing-in of the bone marrow and peripheral blood EPCs, their reparability has been extensively studied in the animal models of myocardial ischemia with encouraging results. Our literature review is a compilation of the lessons learned from the use of EPCs in experimental animal models with emphasis on the in vitro manipulation and delivery strategies to enhance their retention, survival and functioning post-engraftment in the heart.

18 May 2022
Verified
Book Chapter
Closed access
PDF file
AAAbdullah Murhaf Al-Khani
Abdullah Murhaf Al-Khani
MKMohamed Abdelghafour Khalifa
Mohamed Abdelghafour Khalifa
KHKhawaja Husnain Haider
Khawaja Husnain Haider